Background: Myeloproliferative neoplasms (MPNs) describe a group of diseases involving the bone marrow (BM). Classical MPNs are classified into chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This classification is based on the presence of Philadelphia (Ph) chromosome (BCR/ABL1). CML is BCR/ABL1-positive while PV, ET, and PMF are negative. JAK2 p. Val617Phe pathological variant is the most associated mutation in BCR/ABL1-negative MPNs. The frequency of JAK2 p. Val617Phe is 90-95% in PV patients, 50-60% in ET, and 40-50% in patients with PMF. Studies on MPL gene led to the revelation of a gain of function pathological variants in JAK2 p. Val617Phe-negative myeloproliferative neoplasms (MPNs). MPL p. W515 L/K pathological variants are the most common across all mutations in MPL gene. The prevalence of these pathological variants over the Egyptian population is not clear enough. In the present study, we aimed to investigate the prevalence of MPL p. W515 L/K pathological variants in the Philadelphia (Ph)negative MPNs over the Egyptian population.
Background
Myeloproliferative neoplasms (MPNs) describe a group of diseases involving the bone marrow where there is a myeloid cell lineage proliferation that leads to an increase in the numbers of erythrocytes, megakaryocytes, or granulocytes in the bloodstream [1] Classical MPNs include chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) according to the World Health Organization (WHO) 2008 classification and the 2016 revision [2, 3] . Classical MPNs are classified according to the presence of Ph-chromosome (BCR/ ABL1), CML is BCR/ABL1-positive while BCR/ABL1negative MPNs include PV, ET, and PMF [4] .
Somatic pathological variant in exon 14 of the JAK2 gene p. Val617Phe is the most associated mutation in BCR/ABL1-negative MPNs. The frequency of JAK2 p. Val617Phe is 90-95% of patients meeting the clinical criteria for PV, 50-60% for ET, and 40-50% for PMF [5] . While JAK2 exon 14 mutation is the most frequent mutation in MPN, about 10% of patients with clinical characteristics of PV, ET, and PMF lack this mutation [5] . Somatic variants in exon 12 of JAK2 gene are found exclusively in PV patients and are detected in one third of PV patients who are p. Val617Phe negative [6] .
Pathological variants causing gain of function in the MPL gene (thrombopoietin receptor) are detected in JAK2-negative ET and PMF patients. The most prominent MPL pathological variants are located at the transmembrane region of the thrombopoietin receptor (TPO) [7] [8] [9] [10] .
The most frequent variants are found at codon 515 of the MPL gene being either p. Trp515Lys or p.Trp515Leu which is commonly referred to as MPL p. W515 L/K. The tryptophan residue (W) at position 515 in the MPL gene is responsible for the inhibition of the MPL transmembrane helix dimerization thus preventing the thrombopoietin-independent activation. The substitution of this residue with another amino acid such as leucine or lysine constitutively activates the JAK-STAT signaling and causes the thrombopoietin receptor to have uncontrolled self-activity leading to MPN [1, [10] [11] [12] [13] . MPL p. W515 L/K variants are not found in PV patients but restricted to 3-5% in ET and 5-10% in PMF [14] .
The prevalence of these mutations over the Egyptian population still is not clear enough. In the present study, we aimed to investigate the frequency of MPL p. W515 L/K pathological variants in Philadelphia (Ph)-negative MPNs over the Egyptian population.
Methods

Patients
A total of 60 patients with MPNs were recruited for this study. All patients were referred to the outpatient clinic of Nasser institute hospital Cairo, Egypt. The study was carried out between February 2016 and January 2018. The diagnosis of MPN was based on the World Health Organization criteria (2016 revision) [3] . All patients were subjected to full clinical examination and laboratory studies. Patients with positive BCR/ABL were excluded. All patients gave informed consent, and the study was carried out per The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments in humans.
Treatment
Low-dose aspirin was given to all PV and ET patients. For PV patients, repeated venesection was done to maintain hematocrit level below 45. Patients with PV/ ET, older than 60 years, and/or with previous history of thrombosis were considered as high risk and were given cytoreductive therapy with hydroxyurea. PMF patients with anemia were treated with repeated blood transfusion, danazol, erythropoietin, and corticosteroids whereas patients with huge splenomegaly were managed by hydroxyurea.
Methods
DNA isolation
Peripheral blood samples were collected at the time of diagnosis on EDTA anticoagulant tubes. Genomic DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen, Germany) (Cat: 51104) according to the manufacturer's instructions. DNA quality and quantity were assessed using Nanodrop.
MPL p. W515 L/K pathological variants analysis
Amplification refractory mutation system (ARMS) PCR technique was used for the screening of MPL W515K/L pathological variants NM_005373.2: (p.Trp515Lys)/(p. Trp515Leu). ARMS PCR assay contains four primers (Table 1 ) in a single PCR tube, two forward and two reverse that are used in different combinations to amplify three probabilities, the internal control, wild allele, and the mutant allele bands. PCR was performed in 25 μl reaction volume using one unit hot start Taq DNA (Cat: 154013297) as previously described by Zhuge et al. 2010 [15] . PCR products were evaluated on 1.5% agarose gel ( Fig. 1 ).
JAK2 p. Val617Phe mutation analysis
JAK2 p. Val617Phe mutation (NM_004972.3) c.1849G>T (p. Val617Phe) was screened using ARMS technique. Two forward primers and two reverse primers were used (Table 2 ) in a single PCR tube to amplify three amplicons, an internal control, a wild allele, and mutant allele bands. PCR reaction contained one unit of Hot start Taq DNA polymerase (Cat: 154013297) as previously described by Chen et al. 2007 [16] . PCR products were analyzed on 2% agarose gel (Fig. 2 ).
Statistical analysis
Data were analyzed using SPSS windows statistical package, version 22. Numeric data were presented as mean and standard deviation or median and range as appropriate. Categorical variables were presented as frequency and percentage. Comparison between the different results regarding categorical data was done using chi-square test (Fisher's exact test). P value less than 0.05 was considered significant, and all tests were two-tailed.
Results
The present study included 60 MPN patients: 14 (23.3%) were diagnosed as PV, 26 (43.3%) as ET, and 20 (33.3%) as PMF. The median age was 51 (22-73) years. No significant difference was detected between the three groups in age or sex, Table 1 Laboratory characteristics Median WBC was 7.7 (1.08-69) × 10 9 /L, Median hemoglobin was 12.9 (3.1-26.3) g/dL and median platelet count was 497.5 (13-2433) × 10 9 /L. Patients diagnosed with PV had significantly higher hemoglobin levels compared to ET and PMF (17.4 ± 2.39 vs. 13 ± 3 .49; 8.7 ± 2.8, p < 0.001) g/dl, respectively. Patients diagnosed with ET had a significantly higher level of platelet count compared to PV and PMF (1099 ± 470 vs. 294 ± 165, 268.45 ± 351.8, p < 0.001) × 10 9 /L, Table 3 .
MPL p. W515 L/K pathological variants
All patients were negative for both pathological variants of the MPL W515 L and W515K JAK2 p. Val617Phe pathological variant JAK2 p. Val617Phe mutation was detected in 28 (46.7%) patients with no significant difference between the three groups, p = 0.143. JAK2 p. Val617Phe pathological variant tended to be associated with the level of hemoglobin in patients with PV compared to ET and PMF (16.689 ± 2.4927 vs. 12.838 ± 2.4808, 8.783 ± 3.6581, p = 0.062).
Symptoms
Fatigue was significantly higher in patients with PMF compared to those with PV and ET (12 (60%), 5 (35.7%), and 6 (23.1%), p = 0.04), respectively. Headache and dizziness were not significantly different between groups.
Signs
Splenomegaly was in 27/60, (45%) of patients. No significant difference was detected between groups regarding hepatomegaly or splenomegaly, Table 1 .
Complications
Eleven (18.3%) MPN patients had bleeding events; bleeding and thrombotic events did not show any significant difference between the three groups, Table 1 .
Discussion
In this study, we investigated the frequency of the pathological variant MPL p. W515 L/K in 60 patients with Ph-negative MPNs. No MPL p. W515 L/K pathological variants were detected in our patients. Our results are consistent with previous studies performed among both Taiwanese and Iranian populations [17, 18] . They screened 88 Taiwanese and 60 [19] . The authors screened all the MPL mutations by using a high-resolution melting analysis (HRM) [19] . Also, Lieu et al. [17] detected higher frequency of MPL p. W515 L/K among ET and PMF compared to that among PV. In this study, 14/60 (23%) of our patients were with PV. Furthermore, the frequency of MPL p. W515 L/K is higher in JAK2-negative MPN [20] . About 50% of our patients were positive for JAK2 p. Val617Phe pathological variant. Screening for MPL p. W515 L/K is recommended for the JAK2 p. Val617Phe-negative MPN [21, 22] . The prevalence of MPL mutations in MPN patients varies across different ethnic groups. In China, Lin et al. [13] [26] . Going to the Middle East, Akpinar et al. screened Turkish MPN patients and found MPL p. W515 L/K pathological variants with a frequency of 2.6% across PMF patients while they did not find any in ET patients [27] . In Iran, Shams et al. screened 105 MPN patients and the frequency was 4.76% [28] .
In this study, our MPN patients showed a much lower median age at diagnosis of 49.5, 45, and 56.5 in PV, ET, and PMF, respectively, compared with other studies which had a higher median age of 59, 55, and 65 in PV, ET, and PMF, respectively [29] [30] [31] . This study revealed lower frequency of Jak2 p. Val617Phe pathological variant across PV and PMF represented in 64.3 and 30%, respectively, when compared to other data worldwide for the incidence of Jak2 p. Val617Phe pathological variant which was represented in 85 and 65.8% [13] , 81.4 and 46.1% [32] , 87.2 and 50% [2] , 100% and 68% [33] , and 90 and 62% [19] of PV and PMF, respectively.
The percentage of ET patients who had splenomegaly at diagnosis was 50% which is considered to be higher than the percentage of other ET patients worldwide (5-20%) [34] . This deviation may be related to endemic parasitic infections like schistosomiasis in Egyptian patients. Also, our ET patients were considered relatively young and the incidence of splenomegaly we reported was high in young patients which is consistent with the results reported by Montanaro et al. [34] .
Conclusion
The current study did not detect any MPL p. W515 L/K pathological variants in the Egyptian population. The frequency of JAK2 p. Val617Phe pathological variant in PV and PMF patients was lower than other studies. MPNs affect Egyptians at a younger age compared to different ethnic groups. There is a high frequency of splenomegaly among Egyptian ET patients compared to other studies over different populations. We recommend further studies on a larger number of patients with MPNs in Egypt.
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